



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

Date: 9th November, 2015

To
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051

Sub: - Outcome of Board Meeting held on 9th November, 2015

Dear Sir,

A meeting of the Board of Directors of the company was held on Monday, the 9th day of November, 2015 at 11.30 A.M. at the Corporate Office of the Company at Indore. The Board *inter-alia* considered and approved the Un-audited Financial Results (both Standalone and Consolidated) of the company for the quarter ended 30th September, 2015.

Please find enclosed herewith Un-audited Financial Results (both Standalone and Consolidated) of the Company along with Limited Review Report by the auditors of the Company on the Un-audited financial results of the Company for the quarter ended 30th September, 2015.

This is for the information of the exchange and members thereof.

You are requested to take the same on record.

Thanking You

For Parenteral Drugs (India) Limited

Madhava
Company Secretary



Encl.: a/a

Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA

Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2015

M5000712ID

PART - I							
Sr. No.	Particulars	Three ended 30/09/2015 Unaudited	Preceding three ended 30/06/2015 Unaudited	Corresponding three ended 30/09/2014 Unaudited	Half Year ended 30/09/2015 Unaudited	Corresponding Half Year ended 30/09/2014 Unaudited	(Rs in Lacs) Previous year ended 31/03/2015 Audited
1	Income from Operation						
	(a) Net Sales/Income from Operations (Net of Excise Duty)	5669.48	5094.76	4746.31	10984.24	10034.24	17589.31
	(b) Other Operating Income	12.85	92.57	2.05	105.42	4.89	69.68
	Total Income From Operation (Net)	5882.33	5187.33	4748.36	11069.66	10039.13	17658.99
2	Expenditure						
	a) Consumption of Material Consumed	973.49	3120.41	2685.02	4093.90	5500.91	8689.93
	b) Purchase of Stock in Trade	3305.18			3305.18		
	c) Change in Inventories of Finished Goods, Work in Progress and Stock in trade	179.00	(104.27)	-368.81	74.73	-174.31	(784.83)
	d) Employee Benefit Expenses	209.98	425.14	444.48	635.12	908.05	1844.36
	e) Depreciation and Amortisation Expenses	525.88	525.88	442.12	1051.76	884.24	2385.06
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	703.23	1218.48	1715.23	1921.71	3334.76	6568.73
	Total Expenses	5896.76	5185.64	4918.04	11082.40	10453.65	18703.25
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)						
		(14.43)	1.69	(169.68)	(12.74)	(414.53)	(1044.26)
4	Other Income						
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items						
		(14.43)	1.69	(169.68)	(12.74)	(414.53)	(1044.26)
6	Finance costs	1055.14	1438.75	1467.93	2493.90	2888.96	5917.34
7	Profit/(Loss) from ordinary activities after finance cost but before Exceptional items	(1,069.57)	(1437.07)	(1,637.61)	(2,506.64)	(3,303.49)	(6961.60)
8	Exceptional items						(40.72)
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(1,069.57)	(1437.07)	(1,637.61)	(2,506.64)	(3,303.49)	(7002.32)
10	Tax Expenses	0.00	6.01	91.89	6.01	183.78	(1593.84)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,069.57)	(1443.08)	(1,729.50)	(2,512.65)	(3,487.27)	(5408.48)
12	Extraordinary items (net of tax expense)		0.00				0.00
13	Net Profit / (Loss) for the period (11 + 12)	(1,069.57)	(1443.08)	(1,729.50)	(2,512.65)	(3,487.27)	(5408.48)
14	Share of profit / (loss) of associates*						
15	Minority interest *						
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,069.57)	(1443.08)	(1,729.50)	(2,512.65)	(3,487.27)	(5408.48)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						6418.93
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)
	(b) Diluted	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)
	(b) Diluted	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.


Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA

Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481





PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ
C
M50007121D

PART II

A PARTICULARS OF SHAREHOLDING

1	Public Shareholding						
	-Number of Shares	7967057	7967057	7967057	7967057	7967057	7967057
	-Percentage of shareholding	26.72%	26.72%	26.72%	26.72%	26.72%	26.72%
2	Promoters and Promoter Group Shareholding **						
	a) Pledged/Encumbered						
	-Number of shares	21,849,243	21,849,243	15076441	21,849,243	15076441	21,849,243
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	69.00%	100.00%	69.00%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	73.28%	73.28%	50.56%	73.28%	50.56%	73.28%
	b) Non-encumbered						
	-Number of shares	-	-	6772802	-	6772802	-
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	31.00%	-	31.00%	-
	-Percentage of Shares (as a % of the total share capital of the Company)	-	-	22.72%	-	22.72%	-
B	Detail of Investor Compliant						
	Pending at the beginning of the quarter			0			
	Received during the quarter			0			
	Disposed of during the quarter			0			
	Remaining unresolved at the end of the quarter			0			

Statement of Assets and Liabilities

Sr. No.	Particulars	30.09.2015	31.03.2015
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4285.42	4035.42
	(b) Reserves and Surplus	32993.67	6538.07
	Sub-total - Shareholders' funds	37279.09	10573.49
2	Call money against Preference Shares	0.00	0.00
3	Minority interest *	0.00	
4	Non-current liabilities		
	(a) Long-term borrowings	41341.18	32975.51
	(b) Deferred tax liabilities (net)	1156.97	1150.96
	Sub-total - Non-current liabilities	42498.15	34126.47
5	Current liabilities		
	(a) Short-term borrowings	8243.18	8130.28
	(b) Trade payables	6589.53	4991.58
	(c) Other current liabilities	5031.86	4813.72
	(d) Short-term provisions	735.08	731.46
	Sub-total - Current liabilities	20599.65	18667.04
	TOTAL - EQUITY AND LIABILITIES	100376.89	63367.00
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	65725.97	29859.29
	(b) Non-current investments	13923.35	13923.35
	(c) Long-term loans and advances	717.70	699.93
	(d) Other non-current assets	0.63	0.63
	Sub-total - Non-current assets	80367.65	44483.20
2	Current assets		
	(a) Inventories	5882.91	5060.01
	(b) Trade receivables	13400.24	13070.68
	(c) Cash and cash equivalents	162.06	205.48
	(d) Short-term loans and advances	352.92	208.87
	(e) Other current assets	211.11	318.76
	Sub-total - Current assets	20009.24	18883.80
	TOTAL - ASSETS	100376.89	63367.00

Corporate Office: Shree Ganesh Chambers, A.B. Road, Naviakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com
Website: www.pdindia.com, CIN: L99999MH1983PLC126481

PDPL PARENTERAL DRUGS (INDIA) LTD.



NOTES :

- 1 The above results were reviewed by statutory auditors and audit committee of the company on 9 th November 2015 and approved by Board of Directors in their meeting held on 9th November 2015
- 2 At the moment the company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
- 3 Company has revalued land situated at village Asrawad , Indore and reserve and surplus and fixed assets includes revaluation reserve of Rs.262.18 crores.
- 4 The figures for previous year/period have been regrouped/rearranged wherever found necessary.
- 5 The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

For and on behalf of Board of Directors

Vinod Kumar Gupta
Whole time Director

Place: Indore

Date: 9th November 2015



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481

PDPL PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2015

PART-I							(Rs in Laacs)
Sr. No.	Particulars	Three months ended 30/09/2015 Unaudited	Preceding three months ended 30/06/2015 Unaudited	Corresponding three months ended 30/09/2014 Unaudited	Half Year ended 30/09/2015 Unaudited	Corresponding Half Year ended 30/09/2014 Unaudited	Previous year ended 31/03/2015 Audited
1	Income from Operation						
	(a) Net Sales/Income from Operations (Net of Excise Duty)	7998.16	8804.81	6767.99	16802.97	14479.27	26266.92
	(b) Other Operating Income	29.53	94.65	3.04	124.18	7.54	96.36
	Total Income From Operation (Net)	8027.69	8899.46	6771.04	16927.15	14486.81	26363.28
2	Expenditure						
	a) Cost of Material Consumed	1914.98	4336.09	4402.15	6251.07	8747.95	14936.95
	b) Purchase of Stock In Trade	3739.94	859.40		4599.34		0.00
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	270.78	297.12	-843.81	567.90	-770.24	(2292.58)
	d) Employee Benefit Expenses	324.58	557.67	540.62	882.25	1137.13	2358.09
	e) Depreciation and Amortisation Expenses	676.14	676.14	574.76	1352.28	1149.66	3097.90
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	1161.79	2059.95	2348.22	3221.74	4777.40	9833.07
	Total Expenses	8088.21	8786.37	7021.94	16874.58	15041.90	27933.43
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(60.52)	113.09	(250.91)	52.57	(555.09)	(1570.15)
4	Other Income						
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(60.52)	113.09	(250.91)	52.57	(555.09)	(1570.15)
6	Finance costs	1341.40	1777.84	1715.86	3119.24	3368.24	7025.18
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional items (5-6)	(1,401.92)	(1,664.75)	(1,966.77)	(3,066.67)	(3,923.33)	(8595.31)
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	40.72
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(1,401.92)	(1,664.75)	(1,966.77)	(3,066.67)	(3,923.33)	(8636.03)
10	Tax Expenses	52.08	58.09	91.89	110.17	183.78	(1872.63)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,454.00)	(1,722.84)	(2,058.66)	(3,176.84)	(4,107.11)	(6763.40)
12	Extraordinary items (net of tax expense / lakhs)						
13	Net Profit / (Loss) for the period (11 + 12)	(1,454.00)	(1,722.84)	(2,058.66)	(3,176.84)	(4,107.11)	(6763.40)
14	Share of profit / (loss) of associates*						
15	Minority interest *						
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,454.00)	(1,722.84)	(2,058.66)	(3,176.84)	(4,107.11)	(6763.40)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						8070.76
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)
	(b) Diluted	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)
	(b) Diluted	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)

Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof

Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA

Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481




PART -II
A PARTICULARS OF SHAREHOLDING

1	Public Shareholding						
	-Number of Shares	7967057	7967057	7967057	7967057	7967057	7967057
	-Percentage of shareholding	26.72%	26.72%	26.72%	26.72%	26.72%	26.72%
2	Promoters and Promoter Group Shareholding **						
	a) Pledged/Encumbered						
	-Number of shares	21,849,243	21,849,243	15076441	21,849,243	15076441	21,849,243
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	69.00%	100.00%	69.00%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	73.28%	73.28%	50.56%	73.28%	50.56%	73.28%
	b) Non-encumbered						
	-Number of shares			6772802		6772802	
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			31.00%		31.00%	
	-Percentage of Shares (as a % of the total share capital of the Company)			22.72%		22.72%	

B	Detail of Investor Compliant	3 months ended (30.09.2015)
	Pending at the beginning of the quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

Statement of Assets and Liabilities

Sr. No.	Particulars	30.09.2015 Unaudited	31.03.2015 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4770.42	4520.42
	(b) Reserves and Surplus	33906.28	8189.81
	Sub-total - Shareholders' funds	38676.70	12710.23
2	Share application money pending allotment	0.00	0.00
3	Minority interest *	65.04	65.04
4	Non-current liabilities		
	(a) Long-term borrowings	47833.90	41228.73
	(b) Deferred tax liabilities (net)	1583.91	1473.75
	Sub-total - Non-current liabilities	49417.81	42702.48
5	Current liabilities		
	(a) Short-term borrowings	10173.75	10153.97
	(b) Trade payables	8726.65	6124.26
	(c) Other current liabilities	7210.77	5830.69
	(d) Short-term provisions	869.08	868.43
	Sub-total - Current liabilities	26980.25	22977.35
	TOTAL - EQUITY AND LIABILITIES	115139.80	78455.10
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	76938.27	41371.21
	(b) Goodwill on consolidation *	12870.65	12870.65
	(c) Non-current investments	1.10	1.10
	(d) Long-term loans and advances	539.96	639.27
	(e) Other non-current assets	86.81	86.80
	Sub-total - Non-current assets	90436.79	54969.03
2	Current assets		
	(a) Inventories	8645.71	8027.25
	(b) Trade receivables	14256.62	13936.67
	(c) Cash and cash equivalents	618.73	308.36
	(d) Short-term loans and advances	758.54	690.60
	(e) Other current assets	423.41	523.18
	Sub-total - Current assets	24703.01	23486.06
	TOTAL - ASSETS	115139.80	78455.10



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481

PARENTERAL DRUGS (INDIA) LTD.



NOTES :

- 1 The above results were reviewed by statutory auditors and audit committee of the company on 9th November 2015 and approved by Board of Directors in their meeting held on 9th November 2015
 - 2 The unaudited financial results of the subsidiary companies have been consolidated.
 - 3 At the moment the company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
 - 4 Parent Company has revalued land situated at village Asrawad, Indore and reserve and surplus and fixed assets includes revaluation reserve of Rs.262.18 crores.
 - 5 The figures for previous year/period have been regrouped/rearranged wherever found necessary.
 - 6 The consolidated financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Prev. Year Ended
		Unaudited 30.09.2015	Unaudited 30.06.2015	Unaudited 30.09.2014	Unaudited 30.09.2015	Unaudited 30.09.2014	Audited 31.03.2015
1	Income from operations & other income	5,882.33	5,187.33	4,748.36	11,069.66	10,039.13	17,658.99
2	Profit/Loss before tax	(1,069.57)	(1,437.07)	(1,637.61)	(2,506.64)	(3,303.49)	(7,902.32)
3	Profit/Loss after tax	(1,069.57)	(1,443.08)	(1,729.50)	(2,512.65)	(3,487.27)	(5,408.48)

For and on behalf of Board of Directors

Vinod Kumar Gupta
Whole time Director

Place: Indore
Date: 9th November 2015



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481

T.N. UNNI & Co.
Chartered Accountants

402, Alankar Point,
4-A, Rajgarh Kothi,
Geeta Bhawan Square,
A.B.Road,
Indore- 452001

Review Report to
National Stock Exchange of India Limited/
Bombay Stock Exchange Limited

We have reviewed the accompanying statement of unaudited financial results of M/s. Parenteral Drugs (India) Limited for the period ended 30th September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: *INDORE*

Date: *9 NOV 2015*

For T.N. UNNI & Co.
Chartered Accountants



T.N. Unni
(Partner)
M. No. 14520
F.R.N. 004890C

PH.: OFF. 4060787 RESI. 2496863 TELEFAX : 2493555